Imaging of Solid Tumors Using FAP-2286
a study on Solid Tumor Cancer, General Metastatic Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California
- Dates
- study startedcompletion around
- Principal Investigator
- by Thomas Hope, MD
Description
Summary
This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.
Details
Initially the investigator(s) will focus on imaging breast, pancreas, sarcoma, prostate cancer, bladder cancer, colon cancer, and head and neck cancer.
STUDY AIMS
- Determine the dosimetry for gallium-68 labelled (68Ga-) and 64Cu- FAP-2286.
- Evaluate the uptake and retention of radiotracer in a variety of solid tumors with FAP-2286.
- Evaluate the ability of FAP-2286 to detect metastatic disease.
PRIMARY OBJECTIVES
- All cohorts: Safety of 68Ga- and 64Cu-FAP-2286.
- Cohort 1a: determine the organ dosimetry of 68Ga-FAP-2286.
- Cohort 1b: determine the organ dosimetry of 64Cu-FAP-2286.
- Cohort 2: To assess the feasibility of detecting tumor uptake using FAP-2286.
- Cohort 3: To determine the feasibility of detecting metastatic disease using FAP-2286.
EXPLORATORY OBJECTIVES
- To detect the sensitivity of FAP-2286 PET compared to conventional imaging for the detection of metastatic disease, and when available sensitivity compared to Fluorodeoxyglucose (FDG) PET (FDG-PET).
- Correlation of FAP-2286 uptake with FAP expression determined by immunohistochemistry.
- Compare biodistribution of 68Ga-FAP-2286 and 64Cu-FAP-2286 in normal organs and blood pool based on renal function.
- Determine impact of administered dose of FAP-2286 on image quality.
- Compare the feasibility of detecting tumor uptake using 68Ga-FAP-2286 and 64Cu-FAP-2286
A repeat radiolabeled FAP-2286 PET may be obtained after initiation of subsequent treatment in order to evaluate changes in PET uptake due to treatment effect. Patients will be followed for up to 3 days after the injection of radiolabeled ligand for evaluation of adverse events.
Keywords
Solid Tumors, Adult, Metastatic Cancer, PET, 68Ga-FAP-2286, 64Cu-FAP-2286, Neoplasm Metastasis, Copper, Gallium-68 labelled (68Ga-) FAP-2286, Positron Emission Tomography (PET) imaging, Copper-64 labeled (64Cu-) FAP-2286
Eligibility
You can join if…
Open to people ages 18 years and up
- Age >= 18 years
- Histopathologically confirmed solid tumors in one of the following cohorts:
- Cohort 1 (n=16): measurable disease is not required for this cohort. i. Agnostic to tumor type. b. Cohort 2 (n=40): Metastatic disease present on conventional imaging defined as having RECIST 1.1 measurable disease or multiple bone metastases.
- Pathologically confirmed breast cancer, pancreatic adenocarcinoma, sarcoma, castrate-resistant prostate cancer, bladder cancer, or colon cancer.
ii. Pathologically confirmed cancer other than noted above (basket subgroup, n=10).
- Cohort 3 (n=30): No evidence of metastatic disease as defined as the absence of RECIST 1.1 measurable disease or bone metastases.
- Patients can be imaged at initial staging with what is judged by the treating physician to be high risk disease and where the presence of metastatic disease would greatly impact treatment planning and prognosis. Patients may also be imaged after definitive therapy (surgery, chemotherapy or radiation therapy) if in the determination of the treating physician or investigator there is a high risk of disease recurrence that would also impact treatment plan and/or prognosis.
ii. Pathologically confirmed head and neck cancer or bladder cancer.
- Ability to understand a written informed consent document, and the willingness to sign it.
You CAN'T join if...
- Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
- Known pregnancy.
Location
- UCSF
accepting new patients
San Francisco California 94143 United States
Lead Scientist at UCSF
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Thomas Hope
- ID
- NCT04621435
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 131 study participants
- Last Updated
Frequently Asked Questions
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT04621435.